Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-1137.64%
operating margin TTM
-1223.89%
revenue TTM
20.41 Million
revenue per share TTM
0.11$
valuation ratios | |
|---|---|
| pe ratio | -8.39 |
| peg ratio | -1.85 |
| price to book ratio | 6.02 |
| price to sales ratio | 95.70 |
| enterprise value multiple | -8.99 |
| price fair value | 6.02 |
profitability ratios | |
|---|---|
| gross profit margin | 84.13% |
| operating profit margin | -1223.89% |
| pretax profit margin | -1137.64% |
| net profit margin | -1137.64% |
| return on assets | -54.61% |
| return on equity | -68.18% |
| return on capital employed | -67.9% |
liquidity ratio | |
|---|---|
| current ratio | 7.02 |
| quick ratio | 7.02 |
| cash ratio | 1.68 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 87.05 |
| days of payables outstanding | 789.70 |
| cash conversion cycle | -702.64 |
| receivables turnover | 4.19 |
| payables turnover | 0.46 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.01 |
| interest coverage | -546.46 |
| cash flow to debt ratio | -48.77 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.37 |
| cash per share | 0.68 |
| operating cash flow per share | -0.37 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -48.77 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -860.43 |
Frequently Asked Questions
When was the last time Arbutus Biopharma Corporation (NASDAQ:ABUS) reported earnings?
Arbutus Biopharma Corporation (ABUS) published its most recent earnings results on 06-11-2024.
What is Arbutus Biopharma Corporation's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Arbutus Biopharma Corporation (NASDAQ:ABUS)'s trailing twelve months ROE is -68.18%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Arbutus Biopharma Corporation (ABUS) currently has a ROA of -54.61%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ABUS's net profit margin stand at?
ABUS reported a profit margin of -1137.64% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ABUS's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 7.02 in the most recent quarter. The quick ratio stood at 7.02, with a Debt/Eq ratio of 0.01.